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rug-Eluting Stents
re Safe and Effective
ight or Wrong?*
lrich Sigwart, MD, FACC, FESC, FRCP
eneva, Switzerland
oronary stents were conceived to make transluminal an-
ioplasty safer and more effective (1). When abrupt closure
fter balloon angioplasty of a proximal left anterior descend-
ng coronary artery stenosis in a patient with double vessel
oronary artery disease was reversed for the first time by the
mplantation of a self-expanding mesh stent during a live
emonstration in Lausanne in 1986, it became clear that
rterial scaffolding might present a significant step forward
n the road to predictable endoluminal therapy.
During the years to come, some sobering facts emerged.
ven if most clinicians accepted the general concept of
tenting, two problems relating to safety and efficiency were
mpeding the universal acceptance of this new revascular-
zation modality: 1) a relatively high thrombotic occlusion
ate (safety), and 2) a one-in-three recurrence rate (reste-
osis), reducing efficiency.
See pages 1350 and 1356
The purely mechanical solution to an important biological
roblem received mixed reports. As late as 1991, stenting was
onsidered “futile” by some experts in the field (2). Stent
hrombosis remained a major preoccupation until, after a
ong and frustrating battle with different anticoagulation
egimens, platelet inhibition (3) presented as the solution to
he safety problem; problem number two (efficiency) defied
ll attempts using systemic therapy. Local treatment ap-
eared as a possible way out.
Brachytherapy was hailed in the mid-1990s as an effective
eans of suppressing the exuberant healing response initi-
ted by trauma and the implantation of a foreign body (4).
he border zone of the irradiated segment, however, re-
ained worrisome, because it seemed to stimulate prolifer-
tion rather than stop it (5). The regulatory strings attached
o this treatment option also prevented its wide adoption.
Apart from the difficult task of choosing the right
ompound, drug-eluting stents (DES) imposed a number of
echnological challenges, including 1) how to fix a sufficient
mount of medication onto the stent surface; 2) how to
uarantee even distribution of drugs into the adjacent tissue;
) how to retain the drug for the required period of time;
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or theo
merican College of Cardiology.
From University Hospital, Geneva, Switzerland.nd 4) how to make sure the carrier matrix would do no
arm. These issues presented a formidable task to industry
nd researchers alike.
At the present time, two drugs—rapamycin (also called
irolimus) and its derivatives, and paclitaxel—have made it
nto large clinical trials and seem to have fundamentally
hanged the way coronary artery disease is being treated.
ther potentially promising compounds have quickly fallen
y the wayside, mainly because of a too-narrow therapeutic
argin. Both of the successful candidates have been used
reviously to treat neoplastic disease or modulate the im-
une response in autoimmune disease and after transplan-
ations. Although trials using stents coated with drugs
ocked into biodegradable polymers are under way, both
urrently used stents use drugs embedded in a nonresorbable
olymer matrix, completely covering the stent struts.
The positive clinical results using this approach are
ndeniable. Even if the very first euphoria that followed the
resentation of the Randomized Study with the Sirolimus-
luting Velocity Balloon-Expandable Stent in the Treat-
ent of Patients with De Novo Native Coronary Artery
esions (RAVEL) (6) data—a proof of concept and safety
rial with sirolimus-eluting stents—was little by little cor-
ected by a somewhat-more realistic appreciation in larger
rials with longer follow-up (7). The two-year follow-up
fter implantation of sirolimus-eluting stents presented by
ng et al. (8) and Weisz et al. (9) in this issue of the Journal
ails to show any undue side effects of the DES during years
ne and two after the index revascularization. The initial
eduction in the rate of restenosis in the 508 patients of the
apamycin-Eluting Stent Evaluated at Rotterdam Cardiol-
gy Hospital (RESEARCH) registry (8), compared with
imilar patients treated during the pre-DES era and ob-
erved over the first six to nine months, was maintained up
o two years. The recipients of these stents were unselected,
onsecutive “real-world” patients with a rather large variety
f coronary artery disease.
The two-year follow-up of the SIRIUS trial seems to
onfirm this impression (9). The follow-up of the initial 1,058
atients assigned randomly to bare metal or sirolimus-
luting stents showed equal distribution of clinical events
etween year 1 and 2 in either group. When one examines
he entire two-year follow-up, the difference in recurrence
etween active stents and bare metal stents is striking: target
esion revascularization rate was 21.3% in the bare metal
tent group as compared with only 5.8% in the sirolimus-
luting stent group. Also, there was no difference in purely
linical hard end points such as death, stent thrombosis, and
yocardial infarction. Unfortunately, possibly because the
riginal trial was conceived for eight-month angiographic
ollow-up, clinical follow-up was only 92%.
Are DES safe and effective, then? The answer seems yes,
ut, in medicine and biology nothing is just black or white.
lthough the patients in the SIRIUS trial received clopidogrel
nly for three months, longer treatment is now recommended.
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Editorial Comment April 4, 2006:1361–2or practical purposes, DES may be considered safe if the
atient can continue taking his or her double antiplatelet
edication without interruption for at least six months,
robably longer. Any planned or unplanned surgery presents
real threat to this strategy (personally, I have made it a
abit to always ask patients before implantation of a DES if
ny type of surgery is planned or pending). As to the
ffectiveness, a clear reduction in clinical events, primarily
arget lesion revascularization—without the dreaded increase
n sub-acute and late thrombosis rate—has been demon-
trated.
Although not yet tested in a randomized controlled trial,
ercutaneous interventions with much lower morbidity are
ow playing in the same league as bypass-surgery. But will
hey remain there? Will bypass-surgery become history?
All will depend on the long-term performance of DES.
dmittedly, the four-year follow-up data of the first 30
atients who received a sirolimus-eluting stent looked
eassuring (10). And, the first substantial two-year data
rom two independent centers showing no excess in late
hrombosis have been published in this issue of the Journal
8,9). So far so good; no reason for panic.
However, there is little doubt that the metal skeleton
arrying the drug is not always state of the art and that the
olymer matrix (which clearly induces inflammatory re-
ponses) may still be good for unpleasant surprises. The
vent rate in patients outside the large trials (11) seems
igher than expected, and some patients, potentially impor-
ant ones, have been lost to follow. A meta-analysis of the
andomized Taxus trials also suggests a small but significant
ncrease in rate of late stent thromboses (G. W. Stone,
ersonal communication, 2005).
Despite all reassurances the race for the optimal antipro-
iferative drug and the best way to put this drug to work is
ot over yet. The two-year clinical follow-up presented in
his issue of the Journal is the second act of the DES story.
he play will go on, and we have to remain as vigilant as
ver. Present-generation DES create a unique medium for
hrombosis after the first few weeks after implantation (12).
elayed healing, inflammation and hypersensitivity, lack of
ndothelialization, and malapposition are some of the po-
ential trouble spots involved. Four years of follow-up
hould be the minimum before any close-to-definite con-
lusion can be drawn. Interventional cardiology does not
eed Vioxx-type publicity!There is still mileage in optimizing stent design and
educing the significant risk of late thrombotic complication
y new ways of delivering appropriate softer drugs without
he use of inert polymers. We ought to be reminded that
ome of the first bare metal stents implanted 20 years ago
re still doing fine. It seems unlikely that currently used
onerodable polymers as drug delivery matrix will survive
or the coming 20 years.
eprint requests and correspondence: Ulrich Sigwart, Professor
nd Chairman, Centre and Division of Cardiology, University
ospital, CH-1211 Geneva, Switzerland. E-mail: Ulrich.
igwart@hcuge.ch.
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